Pr ecis: The findings from this preclinical study support an argument that the cell of origin of intrahepatic cholangiocarcinoma is able to arise from biliary epithelia, with potential therapeutic implications for this treatmentrefractory cancer.
Pr ecis: These seminal results show how the administration of immune checkpoint inhibitors with cancer vaccines may vastly improve their antitumor efficacy, a harbinger of great promise for this type of active immunotherapy in cancer treatment.
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Accumulation of Cytosolic Calcium Induces Necroptotic Cell Death in Human Neuroblastoma
Motonari Nomura, Ayumi Ueno, Kotaro Saga, Masahiro Fukuzawa, and Yasufumi Kaneda
Pr ecis: These findings define an upstream pathway for activation of the programmed necrosis process known as necroptosis, with potential therapeutic implications in cancer cells. Pr ecis: This study offers a preclinical proof of concept for a novel antitumor agent with promise as a broad-acting therapeutic in many types of human cancer. 
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TF-011-MMAE (HuMax-TF-ADC), an antibody-drug conjugate composed of a tissue factor-specific antibody, a protease-cleavable linker, and the microtubule disrupting agent monomethyl auristatin E, is a novel antitumor agent with promise as a broad-acting therapeutic in many types of human cancer. The antitumor activity of TF-011-MMAE is dependent on binding to tissue factor-positive tumor cells, followed by highly efficient internalization and lysosomal targeting, which allows intracellular release of the auristatin and subsequent tumor cell killing. After three hours of incubation with tissue factor-expressing ovarian cancer cells, TF-011 (green), the antibody backbone of TF-011-MMAE, colocalized with the lysosomal marker LAMP-1 (red). Colocalization of TF-011 and LAMP-1 (yellow) demonstrates that, upon target binding, TF-011 is rapidly targeted to the lysosomal compartment. For details, see article by Breij and colleagues on page 1214.
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